QS Investors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 16.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 251,943 shares of the company’s stock after selling 50,397 shares during the quarter. QS Investors LLC’s holdings in Johnson & Johnson were worth $33,330,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. State Street Corp grew its stake in shares of Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. FMR LLC grew its stake in shares of Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Johnson & Johnson by 4.5% during the second quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock worth $2,363,788,000 after purchasing an additional 771,039 shares in the last quarter. 65.89% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (JNJ) traded up $0.58 during trading hours on Monday, hitting $140.59. 5,101,300 shares of the stock were exchanged, compared to its average volume of 5,868,289. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $377,697.84, a PE ratio of 19.69, a price-to-earnings-growth ratio of 2.86 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the prior year, the company earned $1.68 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.39%. Johnson & Johnson’s payout ratio is 58.33%.
A number of equities analysts recently commented on JNJ shares. BMO Capital Markets reiterated a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. UBS reiterated a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research note on Thursday, August 31st. Cowen set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $144.59.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by QS Investors LLC” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/11/johnson-johnson-jnj-shares-sold-by-qs-investors-llc.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.